Marksans Pharma

The upward movement in Marksans Pharma's share price came after the company announced that its wholly owned subsidiary, Relonchem in the UK, had received marketing authorisation for its products

Stocks to buy today: CCL Products (India) has shown renewed growth in the last couple of weeks, while Marksans Pharma has experienced a gradual resurgence over the last couple of trading sessions

Marksans Pharma shares rose 5 per cent after 10.27 million shares changed hands via multiple pre-market block trades

At 11:20 PM, Marksans Pharma shares pared gains and were trading merely 0.08 per cent higher at Rs 238 per share. In comparison, BSE Sensex was trading 0.10 per cent lower at 81,247.08 level.

The products will be manufactured at the Verna, Goa facility, and will be marketed & distributed in Australian markets through the Marksans Pharma's subsidiary Nova Pharmaceuticals Australasia Pty

The northward move in Marksans Pharma came after the company's wholly-owned subsidiary, Relonchem, received Marketing Authorisation for the product Baclofen 10 mg Tablets from UK MHRA

The management anticipates stronger performance in the coming quarters due to the company's upcoming new launches, the onset of the winter season and scaling up of the TEVA facility.

Marksans Pharma Ltd on Friday said it has received final approval from the US health regulator for its generic version of Loratadine tablets indicated in the treatment of allergic rhinitis. The approval by the US Food and Drug Administration (USFDA) is for the company's abbreviated new drug application (ANDA) for Loratadine tablets of strength 10 mg, Marksans Pharma said in a regulatory filing. Loratadine tablets are indicated for the treatment of allergic rhinitis caused by pollen and upper respiratory tract allergy for over-the-counter (OTC) use. This product is a generic version of Clartin tablet in the same strength as Bayer Healthcare, the company added. Loratadine is an antihistamine that treats symptoms such as itching, runny nose, watery eyes, and sneezing from "hay fever" and other allergies, it added.

Shares of Marksans Pharma gained up to 3.23 per cent at Rs 319 a piece on the BSE in Friday's intraday deals

The surge in the stock price came after the company announced that its wholly owned subsidiary (WOS) Relonchem Limited has secured Marketing Authorisation from UKMHRA for three products.

Shares of Marksans Pharma soared up to 1.98 per cent at Rs 220.14 per share on the BSE in Tuesday's intraday trade

The US & North America Formulation biz reported growth of 29.8% YoY in Q1FY25, on account of incremental revenue from new product launches, and increase in the share of existing customers.

Marksans Pharma's net profit fell 4.5 per cent on a year-on-year (Y-o-Y) basis to Rs 78.3 crore in the March quarter of FY24, from Rs 82 crore in the March quarter of FY23

The product will be manufactured at Marksans Pharma's formulation manufacturing facility in Goa, India

Marksans Pharma Ltd on Friday said it has received final approval from the US health regulator for its generic version of Famotidine tablets indicated for the treatment of acid indigestion and heartburn. The approval granted by the US Food & Drugs Administration (USFDA) for the abbreviated new drug application (ANDA) of Famotidine tablets is for strengths of 10 mg and 20 mg for over-the-counter (OTC) use, Marksans Pharma said in a regulatory filing. The product is bioequivalent to the reference-listed drug (RLD), Pepcid AC tablets, a registered trademark of Johnson & Johnson Consumer Inc which has sales of over USD 200 million in the US market, it added. "We are delighted to continue OTC gastro portfolio expansion for our customers and it will help us to fulfill an important therapy gap created in the Antacids market due to Ranitidine withdrawal," Marksans Pharma Managing Director Mark Saldanha said. The company's OTC Famotidine tablets are acid reducers, used to treat ...

Drug firm Marksans Pharma on Tuesday said it has inked a pact with Tevapharm India to acquire its Goa-based bulk pharmaceutical formulations business. The company has entered into a business transfer agreement with Tevapharm to acquire its business relating to the manufacture and supply of bulk pharmaceutical formulations as a going concern on a slump sale basis. The drug firm has agreed to retain the site employees with existing terms of employment, Marksans Pharma said in a regulatory filing. The transaction is in cash consideration and expected to be finalised by April 1, 2023, subject to the closing conditions, it said, but did not specify the deal value. Teva's affiliate Watson Pharma will continue to own and operate Tevapharm's other manufacturing site at Verna, Goa, the drug firm added. Marksans will continue to supply Teva's affiliates with certain products until the end of FY23 as part of the agreement, which can be extended further with mutual agreement, it said. "The .

Marksans Pharma and Novartis India from the S&P BSE Healthcare index zoomed 20 per cent each

The stock surged 9% to Rs 56.65, trading close to its 52-week high of Rs 58.30 hit on October 4, 16.

The stock surged 20% to Rs 48.70 on the BSE in intra-day trade on back of heavy volumes.

The stock rallied 12% to Rs 53.55 after the USFDA approval for loratadine liquid filed capsules 10 mg